Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact
Eli Lilly secured FDA approval for its once-weekly insulin Onswik and announced a $3.25 billion research partnership with InnoCare Pharma.
Share
Why It Matters
Lilly got approval for a new insulin medicine patients take once weekly. The company also paid billions to work with another drug maker on new treatments.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.